IKT

Inhibikase Therapeutics

IKT50

Penny Stock

$1.96arrow_drop_down3.65%-$0.07

Penny Stock

IKT

IKT50

$1.96

arrow_drop_down3.65%-$0.07

Penny Stock

Performance History

Key Stats
Open	$2.35
Prev. Close	$2.36
EPS	-3.21
Dividend	Non-Dividend
Next Earnings Date	-
Dividend Yield %	-
Market Cap	$134.83M
PE Ratio	-

	LOW	HIGH
Day Range	1.95	2.36
52 Week Range	0.79	3.82

Ratios

Revenue	-



EBITDA Margin %	-

EPS	-3.21

Score Breakdown

Welcome to Stocklytics

Don't miss out on the opportunity to stay ahead in the ever-changing world of finance.

Analyst Forecast

Period: Next 12 Months

•

Analyst Ratings

•

About Inhibikase Therapeutics (IKT)

Inhibikase Therapeutics Inc (IKT) is a biopharmaceutical company that focuses on developing novel therapeutics for the treatment of infectious diseases. The company's pipeline includes multiple drug candidates targeting various pathogens, including viruses and bacteria. With a strong emphasis on research and development, Inhibikase Therapeutics is dedicated to discovering innovative solutions to combat infectious diseases that pose significant global health threats.

The stock price history of Inhibikase Therapeutics Inc (IKT) reflects the volatility and uncertainty inherent in the biotechnology sector. As a development-stage company, the market value of IKT can fluctuate significantly based on news and clinical trial results. Investors should carefully consider the risks associated with investing in early-stage biopharmaceutical companies before making any investment decisions.

Websitecall_made

Sector: Healthcare
Industry: Biotechnology
CEO: Dr. Milton H. Werner Ph.D.
Headquarters: Atlanta
Employees: 6
Exchange: NASDAQ

add Inhibikase Therapeutics to watchlist

Keep an eye on Inhibikase Therapeutics

Adding the right stocks to your watchlist can provide valuable insights and opportunities for strategic decision-making.

Frequently Asked Questions

help

What is Inhibikase Therapeutics 's (IKT) price per share?

The current price per share for Inhibikase Therapeutics (IKT) is $1.97. The stock has seen a price change of -$0.07 recently, indicating a -3.66% change. This reflects the stock's recent market performance and investor sentiment.

help

What is the 52-week high and low for Inhibikase Therapeutics (IKT)?

For Inhibikase Therapeutics (IKT), the 52-week high is $3.82, which is 94.4% from the current price. The 52-week low is $0.79, the current price is 148.73% above the 52-week low. This gives investors an insight into the stock's volatility and price range over the past year.

help

Is Inhibikase Therapeutics (IKT) a growth stock?

Inhibikase Therapeutics (IKT) has shown an average price growth of -6.8% over the past three years. It has received a score of 43 out of 100 based on the Stocklytics formula. The interpretation of this score in terms of classifying Inhibikase Therapeutics as a growth stock may vary, considering it is one of many factors investors might evaluate, including market trends, financial performance, and future prospects of the company.

help

What is Inhibikase Therapeutics (IKT) stock price performance year to date (YTD)?

As of the latest data, Inhibikase Therapeutics (IKT) has a year-to-date price change of 47.54%. Over the past month, the stock has experienced a price change of -16.38%. Over the last three months, the change has been 53.52%. Over the past six months, the figure is 13.58%.

help

Is Inhibikase Therapeutics (IKT) a profitable company?

Inhibikase Therapeutics (IKT) has a net income of -$19.03M, which represents the company's total earnings after all expenses have been deducted from revenues. The gross margin of indicates the percentage of revenue that exceeds the cost of goods sold, and the operating margin of -23.89K% reflects the percentage of revenue remaining after covering variable production costs, highlighting the efficiency of the company's core operations. Total revenue stands at , although specific revenue growth data is currently not available. Operating income is noted at -$20.09M. Furthermore, the EBITDA is -$18.98M.

help

What is the market capitalization of Inhibikase Therapeutics (IKT)?

Inhibikase Therapeutics (IKT) has a market capitalization of $131.55M. The average daily trading volume is 2, indicating the stock's liquidity and investor engagement.

News

HEALTH

CLINICAL STUDY

Jun 17, 2024

Inhibikase Therapeutics Completes Enrollment of the Phase 2 ‘201’ Trial Evaluating Risvodetinib in Untreated Parkinson’s Disease

CLINICAL STUDY

Jun 5, 2024

Inhibikase Therapeutics Announces Expansion to its Therapeutic Pipeline and Updates its Research and Development Programs

CHANGES IN COMPANY'S OWN SHARES

May 20, 2024

Inhibikase Therapeutics Announces Pricing of Registered Direct Offering and Warrant Inducement, Priced At-The-Market for Aggregate Gross Proceeds of $4.0 Million

EARNINGS RELEASES AND OPERATING RESULTS

May 16, 2024

Inhibikase Therapeutics Reports First Quarter Financial Results and Highlights Recent Period Activity

REGULATORY INFORMATION

May 15, 2024

Inhibikase Therapeutics Announces Request for Withdrawal of S-1 Registration Statement

HEALTH

May 9, 2024

Inhibikase Therapeutics Announces Final Pre-IND Meeting Outcomes for IkT-001Pro as a Treatment for Pulmonary Arterial Hypertension